Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication
The final trial reported that efficacy results for cycles B and C were not analyzed because of substantial crossover. The first-cycle benefit therefore should not be presented as three separately demonstrated cycles of efficacy.
Later treatment histories became mixed
The study included different continuation and crossover arrangements across its phases. A recruitment-related amendment also permitted some participants to switch when significant symptoms occurred. By later cycles, treatment received could reflect both the original allocation and subsequent clinical experience or preference.
Safety reporting was not the missing efficacy analysis
The authors included later adverse-event information, partly after unblinding and crossover. That reporting did not replace an analyzed controlled efficacy comparison for each later cycle. Continued observations can answer some safety questions without supplying the same causal comparison as the randomized first cycle.
Durability remains a distinct question
The favorable primary result concerned cycle A and the first 120 hours after chemotherapy. It did not establish unchanged benefit across every later cycle or a long-term response probability. This limitation does not negate the first-cycle finding. It identifies where repeated treatment experience was not analyzed as a confirmatory extension of that finding. Claims about sustained benefit should retain that boundary rather than multiplying the observed primary effect by the number of planned cycles.
Related analysis: the trial’s main results and limitations.
